Transfection efficiency of adenoviral vector AD5/F35 to malignant hematopoietic cells of different origins.
- Author:
Kai WABG
1
;
Jian-Qinag PENG
;
Zhen-Hua YUAN
;
Xiao-Bin WU
Author Information
1. Department of Hematology, Xianya Hospital, Changsha 410008, China.
- Publication Type:Journal Article
- MeSH:
Adenoviruses, Human;
genetics;
Gene Transfer Techniques;
Genetic Vectors;
genetics;
Hematologic Neoplasms;
genetics;
pathology;
Hematopoietic Stem Cells;
Humans;
K562 Cells;
Tumor Cells, Cultured
- From:
Journal of Experimental Hematology
2006;14(3):525-528
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the transfection efficiency of adenoviral vector AD5/F35 to hematopoietic malignant cells lines of various origins and AD5/F35 cytotoxicity. The hematologic malignant cell lines of various origins were transfected by AD5/F35-EGFP at different multiple of infection (MOI) and AD5-EGFP was used as control; the proportion of fluorescence positive cells was detected by flow cytometry; the killing effect of virus on infective target cells was assayed by MTT and observed by fluorescence microscopy. The results showed that the transfection efficiency of AD5/F35 vector to cell line of myeloid origin was > 99% at MOI = 30, the transfective efficiency of AD5 vector was 26.4% at MOI = 1,000; the transfection efficiency of AD5/F35 vector and AD5 vector to cell line of B cell origin were 11.7% and 5.7%, respectively, at MOI = 1,000. AD5/F35 and AD5 vectors could not effectively transfect cells of T cell origin, no fluorescence positive cells were detected at MOI = 1,000; no significant killing effect of AD5/F35 vector on infective target cells was observed at MOI = 1,000. It is concluded that AD5/F35 vector infection has definite selectivity to hematologic malignant cells of various origin, the infection ability of AD5/F35 vector to cells of myeloid origin is stronger than that to cells of B cell origin, the cytotoxicity of AD5/F35 vector to infective target cells is small. The AD5/F35 vector is preferable to AD5 vector in respect of infection ability and offers good prospects of application in gene therapy for myeloid leukemia cells as target cells.
